Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan 23:6:13-24.
doi: 10.4137/CMWH.S10483. eCollection 2013.

Abnormal bleeding during menopause hormone therapy: insights for clinical management

Sebastião Freitas de Medeiros  1 , Márcia Marly Winck Yamamoto  2 , Jacklyne Silva Barbosa  2
Affiliations
Review

Abnormal bleeding during menopause hormone therapy: insights for clinical management

Sebastião Freitas de Medeiros et al. Clin Med Insights Womens Health. .

Abstract

Objective: Our objective was to review the involved mechanisms and propose actions for controlling/treating abnormal uterine bleeding during climacteric hormone therapy.

Methods: A systemic search of the databases SciELO, MEDLINE, and Pubmed was performed for identifying relevant publications on normal endometrial bleeding, abnormal uterine bleeding, and hormone therapy bleeding.

Results: Before starting hormone therapy, it is essential to exclude any abnormal organic condition, identify women at higher risk for bleeding, and adapt the regimen to suit eachwoman's characteristics. Abnormal bleeding with progesterone/progestogen only, combined sequential, or combined continuous regimens may be corrected by changing the progestogen, adjusting the progestogen or estrogen/progestogen doses, or even switching the initial regimen to other formulation.

Conclusion: To diminish the occurrence of abnormal bleeding during hormone therapy (HT), it is important to tailor the regimen to the needs of individual women and identify those with higher risk of bleeding. The use of new agents as adjuvant therapies for decreasing abnormal bleeding in women on HT awaits future studies.

Keywords: abnormal uterine bleeding; climacteric; endometrium; hormone therapy; menopause.

PubMed Disclaimer

References

    1. de Medeiros SF, Yamamoto MMW, Oliveira VN. Climacteric complaints among very low-income women from a tropical region of Brazil. São Paulo Med J. 2006;124:214–8. - PMC - PubMed
    1. Green R, Santoro N. Menopausal symptoms and ethnicity: the Study of Women’s Health Across the Nation. Womens Health (Lond Engl) 2009;5:127–33. - PMC - PubMed
    1. Blümel JE, Chedraui P, Baron G, et al. For the Collaborative Group for Research of the Climacteric in Latin America (REDLINC). A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause. 2011;18:778–85. - PubMed
    1. Tonkelaar ID, Oddens BJ. Determinants of long-term hormone replacement therapy and reasons for early discontinuation. Obstet Gynecol. 2000;95:507–12. - PubMed
    1. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menop Stud. 1996;41:11–5. - PubMed

LinkOut - more resources